Trial Profile
MUC-1 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Pancreatic Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2018
Price :
$35
*
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Innovative Cellular Therapeutics
- 27 Feb 2018 New trial record